Bernard E, Garraffo R, Leclercq-Boscherel B, Garret C, Bidault R, Dellamonica P; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 1 (abstract no. 6).
Univ. Hosp., Nice
GFX is a new fluoroquinolone with antibacterial activity including bacteria responsible for lower respiratory tract infections and sexually transmitted diseases. GFX is metabolised by cytochrome P4501A2 and 3A4 and could be administered concomitantly with RIF, a reference inducer of CYP3A4. To investigate the effect of RIF on GFX pharmacokinetics, 16 healthy volunteers (8 males and 8 females) received first 600 mg of GFX once daily for 7 days (Period 1). After a 7-14 days wash-out period, 600 mg of GFX with 600 mg of RIF were administered once daily for 7 days (Period 2). Blood samples were collected on day 7 of each period at different times over 72 h. Plasma concentrations of GFX were assayed by HPLC with fluorescence detection. PK parameters (geometric LS means) were compared with ANOVA and Wilcoxon test. [table: see text] There is no statistical difference on C[max] and T[max] but a 30% decrease AUC. The clinical relevance of this moderate drug-drug interaction is not known and these results should be considered in the event of co-administration of grepafloxacin with rifampin.
Publication Types:
Keywords:
- Area Under Curve
- CYP3A protein, human
- Chromatography, High Pressure Liquid
- Cytochrome P-450 Enzyme System
- Drug Interactions
- Female
- Fluoroquinolones
- Humans
- Male
- Piperazines
- Rifampin
- grepafloxacin
Other ID:
UI: 102244620
From Meeting Abstracts